Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Research Roundtable on Patient Experiences and Long-Term Impact image

Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Research Roundtable on Patient Experiences and Long-Term Impact

Can't make it to the event?
We send a recording to all registered participants of the event!
Dec 18, 2026
02:00PM - 03:00PM EST
Online Event
Overview

Join us for an informative and supportive roundtable designed for multiple myeloma patients and caregivers as we share critical findings from a recent patient-centered research study on bortezomib-induced peripheral neuropathy (BIPN). Led by study investigators Dr. Rafael Fonseca, Dr. Valentina Cardenas, Jay Hydren, PhD, from the HealthTree Foundation, alongside patient participants, this session focuses on understanding the lived patient experience and daily functional impact of neuropathy. Rather than viewing neuropathy as merely a temporary or easily managed side effect, the discussion highlights real-world evidence showing that BIPN is frequently long-lasting or permanent, even with modern weekly and subcutaneous dosing.

Grounded in authentic patient voices and survey data from over 300 individuals, the panel will explore how nerve symptoms intersect with mobility, sleep, independence, and overall quality of life. The conversation will examine the hidden day-to-day challenges (such as balance issues, fear of falling, and career changes) while addressing the gaps in clinician symptom grading, anticipatory counseling, and the role of alternative proteasome inhibitors. Whether you are navigating neuropathy yourself, preparing for treatment, or supporting a loved one, you will gain practical insights and vocabulary to help you feel empowered during conversations with your care team.

Agenda
2:00 PM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and our featured speakers Dr. Rafael Fonseca, Dr. Valentina Cardenas Castro, & Jay Hydren, PhD

2:05 PM
Presentation
Dr. Rafael Fonseca, Dr. Valentina Cardenas Castro, & Jay Hydren, PhD

Our guest panel shares critical findings on peripheral neuropathy (BIPN).

2:35 PM
Questions and Answers
Audience

Come with your questions we will answer them!

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Healthtree contact Rafael Fonseca, MD

Rafael Fonseca, MD

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center…

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, FL, and a fellowship in Hematology and Medical Oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a Clinical Investigator for the Damon Runyon Cancer Research Fund. Dr Fonseca’s practice and research have focused on the diagnosis and treatment of plasma cell disorders. He leads the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers to better understand the genetic nature of malignant plasma cells, real world evidence analysis, myeloma bone disease, prognostic markers, pharmacoeconomics and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials. He also has served as consultant to multiple companies including AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS, GSK, Janssen, Karyopharm, Pfizer, Regeneron, and Sanofi. He is a member of the Scientific Advisory Board of Caris Life Sciences, Ryght, Fortvita and Xenagos. He is a member of the Board of Directors for Antengene. He holds the patent for FISH prognostication in myeloma. He has over 400 peer reviewed publications with an associated H index of 135 with 73,278 citations (Google Scholar October 2026). Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. He was awarded in 2023 the Cyril-Rozman prize by the Spanish Society of Hematology and Hematotherapy. He was awarded a Doctor honoris causa by the Universidad de San Pablo, Argentina in February 2023. He was inducted into the Giants of Cancer Care in 2024. Dr Fonseca holds memberships and has served in positions for organizations such as the ASCO, ASH and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE, CPTAC U01), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the Damon Runyon Cancer Research Fund, Paula and Rodger Riney Foundation and others. Dr Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor.
Healthtree contact Jay Hydren, PhD, CSCS

Jay Hydren, PhD, CSCS

I’m a clinical researcher, with over 14 years of experience investigating various aspects of human health, nutrition and physiology.

I’m a clinical researcher, with over 15 years of experience investigating various aspects of human health, nutrition and physiology. My PhD encompassed the broad topics of nutrition and integrative physiology with particular focus on age related diseases and vascular health. My most recent work focuses on accelerating a cure and treatments for Multiple Myeloma. I’m also working to improve patient experiences and decision-making processes for cancer treatment and care. To complement these critical research efforts, I enjoy hiking and skiing in Utah and surrounding states, along with training my dog and digital photography.
Healthtree contact Valentina Cardenas Castro, MD

Valentina Cardenas Castro, MD

Valentina Cardenas Castro, MD, is a Postdoctoral Research Fellow in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. She earned her medical degree from Universidad del Norte in Barranquilla, Colombia. After graduating, she continued her clinical work serving underserved communities and caring for both pediatric and adult patients. During this time, she developed a particular interest in hematology and in understanding how complex hematologic conditions affect patients throughout diverse clinical and socioeconomic settings. Driven by her growing interest in hematology and clinical research, Dr. Cardenas moved to the United States to further develop her university and research training. She currently serves as a Research Fellow in Health Future Sciences under the mentorship of Dr. Rafael Fonseca. Her research focuses on multiple myeloma, with particular emphasis on clinical outcomes, prognostic factors, and the role of immunoinflammatory markers in patients receiving immune-based therapies. She has presented her work at the American Society of Hematology (ASH) Annual Meeting for two consecutive years and has received an ASH Abstract Achievement Award. Based on these experiences, she has developed expertise in clinical research methodology, statistical analysis, and examining complex clinical data, while aiding research to better understand the factors that affect treatment response and outcomes in patients with multiple myeloma. Her progression from caring for underserved communities to conducting multiple myeloma research in the United States has shaped her commitment to combining patient-centered medicine with rigorous clinical investigation. She hopes to continue building a career at the intersection of hematology, clinical care, and research, using perspectives from both her clinical and research experiences to advance understanding of hematologic diseases and ultimately improve patient outcomes.